Stock Spotlight Archives - Page 222 of 390

FridayDec 11, 2020 2:53 pm

QualityStocksNewsBreaks – Mobius Interactive Ltd.’s ‘Playbook’ Targets ‘Gamers at Heart’

Mobius Interactive is an online gaming operator featuring unique offerings for diverse demographic groups. The company’s website showcases its strategy, telling visitors it is designed for “gamers at heart” who enjoy almost every type of online game imaginable, including sports betting and casino play. A recent article discussing this reads, “Mobius has partnered with leading and award-winning eSports and iGaming platform Ultra Play. With years of experience in eSports and betting operations, Ultra Play provides cutting-edge betting technology and innovative concepts that include partial and complete cashout, livestream and statistics, easy-to-navigate customer database, multicurrency and adjustable exchange rates, data analytics…

FridayDec 11, 2020 2:46 pm

QualityStocksNewsBreaks – Brain Scientific Inc. (BRSF) Engages Dalmore Group for Expert Strategic Advice, Innovative Solutions

Brain Scientific (OTCQB: BRSF), a commercial-stage health-care company focused on developing innovative and proprietary medical devices and software, recently entered into a strategic partnership with the Dalmore Group. A member of FINRA and SIPC, the Dalmore Group maintains an active presence in the Regulation A+ equity funding space. The company is one of the world’s most active broker-dealers and has served on more than 50 RegA+ offerings in the past 12 months, raising more than $1 billion of capital in 2019. The Dalmore Group secures the majority of its clients by referral from securities attorneys and industry participants. A recent…

FridayDec 11, 2020 2:34 pm

QualityStocksNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. Technological advances have greatly increased the life span for CF patients. While children with CF rarely made it to elementary school age in the 1950s, the median age of survival for a CF patient…

ThursdayDec 10, 2020 1:56 pm

QualityStocksNewsBreaks – Rritual Superfoods Inc. Holds Key Certification in Emerging Market

Rritual, a plant-based consumer brand, is a therapeutic foods innovator that is gaining attention as it helps build the emerging new market for healthful mushroom elixirs as a beneficial superfood. On the heels of its initial product launch and after snagging an ECRM Buyer’s Choice Award for its attractive marketing and growing market presence, Rritual has secured organic certification from the U.S. Department of Agriculture (“USDA”). The certification provides “trusted, third-party validation of the quality of Rritual’s products” beyond the unregulated claims of many others featuring “all-natural” ingredients, according to Rritual CEO David Kerbel (https://ibn.fm/DZS67). “We have a premium lineup…

ThursdayDec 10, 2020 1:40 pm

QualityStocksNewsBreaks – Net Element Inc. (NASDAQ: NETE) to Drive into US EV Market in Style, Speed via K50 Dragonfly

Net Element (NASDAQ: NETE) is a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc. The merger is optimally timed as more and more regulations aim to require and encourage adoption of purely electric automobiles as a replacement to conventional combustion engine-powered cars. A recent article discussing the company’s positioning reads, “Net Element and Mullen Technologies have revealed plans to begin their foray into the U.S. electric vehicle market through their partnership with Chinese EVET manufacturer, Qiantu Motors, with the aim…

WednesdayDec 09, 2020 2:49 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) on Track to Launch BaroShear K45 Nanoemulsification System in 2021

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative solutions for the worldwide life science and other industries, recently reported its third-quarter financial results and provided a business update, which included initial expectations for 2021 (https://ibn.fm/8PNFi). Among the updates, the Q3 2020 Form 10-Q financial report outlines measurable progress in three important areas: key operational and technical projects; revenue increases in the company’s products and services offerings; and important structuring improvements in the reduction of arduous, variable-rate convertible debt. A recent article discussing this reads, “Providing other updates and plans for 2021, the Form 10-Q report also mentioned that Pressure…

WednesdayDec 09, 2020 2:37 pm

QualityStocksNewsBreaks – Why Innovative Payment Solutions Inc. (IPSI) Is ‘One to Watch’

Innovative Payment Solutions (OTCQB: IPSI) is a digital payment technology service company that provides cutting-edge solutions for consumers and service providers. Leveraging its proprietary fintech payment architecture, the company is focused on building a 21st century payment platform. IPSI has spent the last five years perfecting its payment platform through its Mexico-based operations, which facilitate over two million users. A recent article discussing the company reads, “IPSI’s new business structure will use the latest technology, including blockchain and an e-wallet, to provide consumers the ability to make payments worldwide. The company’s innovative ecosystem will include multiple devices, such as POS…

TuesdayDec 08, 2020 2:36 pm

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Stands Distinct Among Many Peers, Public Companies with Debt-Free Status

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading producer of uranium in the United States, recently announced a corporate update and financial results for the quarter ended Sept. 30, 2020 (https://ibn.fm/CEDLQ). In addition to being debt free, Energy Fuels had working capital of $44.7 million at the end of Q3 2020, which is a 17% increase over Q2 2020. An article discussing Energy Fuels’ ability to achieve a debt-free status quotes the company’s president and CEO Mark S. Chalmers, who stated, “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce…

TuesdayDec 08, 2020 2:24 pm

QualityStocksNewsBreaks – Friendable Inc.’s (FDBL) Fan Pass Creates ‘Hybrid’ Model for Virtual Performances Around the World

Friendable (OTC: FDBL), a mobile technology and marketing company that leverages proprietary applications to connect and engage users, has achieved record increases in new artists to its live streaming platform. Fan Pass, the company’s flagship product, provides exclusive content channels, live streaming events, promotional support, fan subscriptions and custom merchandise designs for artists at all levels, assisting them to build new revenue streams. “As the uncertainty continues around live venues and performances, we feel even stronger demand from artists seeking the foundational elements of performing from the virtual stage,” said Friendable CEO Robert A. Rositano Jr. “No matter how the…

TuesdayDec 08, 2020 2:14 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2…

Site Search

Company Search

Category: Stock Spotlight